• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vascular Therapies raises $12m for drug-eluting vascular access implant

October 15, 2018 By Sarah Faulkner

Vascular Therapies - updated logoVascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC.

The Cresskill, N.J.-based company is developing a sirolimus-eluting collagen implant for patients with end-stage renal disease. The bioresorbable drug-delivery system is designed to keep open a portal of entry into a patient’s vascular system for hemodialysis.

Roughly 70% of ESRD patients depend on hemodialysis, according to Vascular Therapies, and patients traditionally undergo treatment three times a week.

To prepare a patient’s body for dialysis, a surgeon connects an artery and a vein in the forearm or upper arm, establishing a “vascular anastomosis” – or an arteriovenous fistula. Once the fistula is created and blood begins to flow, it begins to widen in a process known as fistula maturation. This process is essential to successfully treating patients using hemodialysis.

But this approach brings about its own set of problems, Vascular Therapies noted. Over time, cells surrounding the fistula begin to rapidly multiply, causing tissue growth. This process narrows the vascular access port, rendering the fistula useless.

Until a fistula is fully mature, patients undergo dialysis using a catheter. Vascular Therapies is investigating whether it can help limit the time patients spend using catheters and lessen the fistula maturation failure rate using its localized drug-delivery implant.

“Reducing the time between surgery and when the fistula can be cannulated successfully for dialysis and minimizing the need for additional, supplementary interventions to help maintain fistula functionality are extremely clinically relevant outcomes. Achieving these endpoints are expected to reduce catheter dwell time and catheter dependence – a much-desired outcome with important implications for patients, dialysis providers and payors,” the company wrote on its website.

Filed Under: Funding Roundup, Pharmaceuticals, Vascular Tagged With: vasculartherapies

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Reader Interactions

Comments

  1. Santosh Kumar says

    February 6, 2019 at 6:16 am

    Greetings! It’s fascinatingly know that collagen implant on its way ( R&D) for AV fistula retention and keep it patent for better flows.

    We were associated with Fresineous Medical Care and we have been involved ESRD disease management and catering to Nephrology Product requirements in India.We would be interested in distribution of Collagen Implant .

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS